Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Adds $200M to Share Repurchase Program

NEW YORK (GenomeWeb) – Myriad Genetics announced today that its board has approved an additional $200 million for its share buyback program.

Since the inception of the repurchase program in 2010, the company said it has bought back approximately $1.1 billion in stock as of the end of its fiscal third quarter at an average share price of $26.16. When reporting its Q3 earnings a month ago, the firm said it bought back approximately 1.2 million shares, or $45 million worth, of common stock during the quarter, and ended Q3 with around $47 million in its current share repurchase authorization.

"Our priorities for capital deployment remain the same. First, internal research and development, followed by acquisitions, and lastly, share repurchases," said CFO Bryan Riggsbee in a statement. "We will continue to opportunistically repurchase shares at valuation thresholds that we believe do not reflect the inherent value of the company and as we look to deploy our capital most effectively to maximize shareholder returns over the long-term."

Myriad's shares were up more than 2 percent to $35.22 in morning trading on the Nasdaq.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.